NasdaqGM:MNKDBiotechs
MannKind (MNKD) Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed?
Earlier this month, Truist Financial began covering MannKind and issued a positive analyst rating, following similar Buy ratings from Wells Fargo and ongoing support from H.C. Wainwright, even after the discontinuation of MNKD-101.
These endorsements coincide with MannKind's latest earnings report, which showed revenue growth despite lower net profit, highlighting analyst confidence in the company’s underlying business developments.
We'll assess how this wave of positive analyst ratings from...